Koppers
KOP NYSE Commodity Chemicals Financials FY2016βFY2025
Koppers' revenue fell 10.2% to $1.9 billion in fiscal 2025. Its operating margin was 8.9%, up from 7.1% a year earlier. Free cash flow was $68 million, up 60.7%. It paid out $45 million in dividends and buybacks, 66% of free cash flow. The diluted share count fell 4.2%.
What Koppers does
No business description yet.
- Legal name
- KOPPERS HOLDINGS INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- β
- Accession Β· CIK
- 0001315257-26-000012
0001315257
Revenue and margins
Koppers had $1.9B of revenue in fiscal 2025, down 10.2% on the year before.
Net income and earnings per share
From fiscal 2016 to 2025, diluted EPS grew 7.8% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $67.5M in fiscal 2025, 3.6% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Koppers returned $44.6M to shareholders in fiscal 2025, 66% of free cash flow. The diluted share count fell 4.2%.
Value Koppers yourself
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
Discounted cash flow
Value per share
β
Adds net cash of β$890M and divides by 20.4M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Balance sheet
Cash, debt and the ratios that show how comfortably Koppers can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $45.5M | $33.3M | $66.5M | $43.9M | $38.0M |
| Debt incl. finance leases | $789M | $825M | $849M | $940M | $928M |
| Net debt / EBITDA | 3.5x | 4.1x | 3.1x | 4.2x | 3.7x |
| Debt / equity | 1.9x | 2.1x | 1.7x | 1.9x | 1.6x |
| Interest coverage | 3.9x | 3.1x | 2.8x | 1.9x | 2.5x |
| Current ratio | 2.2x | 2.0x | 2.1x | 2.1x | 2.9x |
| Quick ratio | 1.1x | 0.9x | 0.9x | 0.9x | 1.1x |
| Total assets | $1.7B | $1.7B | $1.8B | $1.9B | $1.9B |
| Total liabilities | $1.3B | $1.3B | $1.3B | $1.4B | $1.3B |
| Shareholders' equity | $407M | $399M | $499M | $489M | $574M |
| Net debt (β = net cash) | $744M | $792M | $783M | $896M | $890M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$5.6M
4 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Ball M LeroyCEO, Director | Sold | 4,000 | $45.96 | $0.2M | Form 4 |
| Aug 19, 2026 | Ball M LeroyCEO, Director | Sold | 3,000 | $45.84 | $0.1M | Form 4 |
| Aug 12, 2026 | Stephen G LucasSVP, Culture and Engagement | Sold | 1,308 | $44.55 | $0.1M | Form 4 |
| Aug 11, 2026 | James A. SullivanPresident and CTO | Sold | 7,500 | $50.00 | $0.4M | Form 4 |
| Aug 10, 2026 | Bradley A PearceCAO | Sold | 2,000 | $51.01 | $0.1M | Form 4 |
| Aug 7, 2026 | James A. SullivanPresident and CTO | Sold | 80,000 | $50.01 | $4.0M | Form 4 |
| Jun 18, 2026 | Ball M LeroyCEO, Director | Sold | 3,412 | $43.90 | $0.1M | Form 4 |
| Jun 11, 2026 | Ball M LeroyCEO, Director | Sold | 4,141 | $41.34 | $0.2M | Form 4 |
| May 13, 2026 | Ball M LeroyCEO, Director | Sold | 2,659 | $42.55 | $0.1M | Form 4 |
| Mar 17, 2026 | Ball M LeroyCEO, Director | Sold | 2,489 | $37.91 | $0.1M | Form 4 |
| Mar 2, 2026 | Ball M LeroyCEO, Director | Sold | 6,275 | $36.87 | $0.2M | Form 4 |
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 8 / 9 | 5 / 9 | 8 / 9 |
| Accruals ratio | β3.2% | β3.6% | β3.5% |
| Altman Z'' | 3.23 | 2.97 | 3.52 |
Similar companies
Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Koppers KOP | $767M | β10.2% | 8.9% | 3.6% | 8.1% | β | 8 | |
| Hawkins HWKN | $2.8B | 11.2% | 11.2% | 7.9% | 13.1% | 34.3x | 4 | Compare β |
| Dow DOW | $23.5B | β7.0% | β | β3.6% | β4.1% | β | 3 | Compare β |
| Quaker Chemical KWR | $2.7B | 2.7% | 2.8% | 4.3% | 1.3% | 27.8x | 5 | Compare β |
| Ashland Global ASH | $3.4B | β13.7% | β42.5% | 2.0% | β17.5% | 69.5x | 5 | Compare β |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.4B | $1.5B | $1.6B | $1.6B | $1.7B | $1.7B | $2.0B | $2.2B | $2.1B | $1.9B |
| Gross profit | $290M | $322M | $302M | $331M | $360M | $334M | $345M | $425M | $423M | $448M |
| Research and development | $6.6M | $9.0M | β | β | β | β | β | β | β | β |
| Operating income | $93.4M | $124M | $84.4M | $125M | $157M | $157M | $138M | $195M | $148M | $168M |
| Interest expense | $50.8M | $42.5M | $54.1M | $61.7M | $48.9M | $40.5M | $44.8M | $71.0M | $76.2M | $66.1M |
| Pretax income | $38.5M | $60.3M | $31.2M | $63.7M | $110M | $120M | $95.4M | $125M | $69.3M | $81.2M |
| Income tax | $11.4M | $29.0M | $25.7M | $0.0M | $21.0M | $34.5M | $31.6M | $34.8M | $20.7M | $25.2M |
| Net income | $29.3M | $29.1M | $23.4M | $66.6M | $122M | $85.2M | $63.4M | $89.2M | $52.4M | $56.0M |
| Diluted EPS | $1.39 | $1.32 | $1.10 | $3.16 | $5.71 | $3.88 | $2.98 | $4.14 | $2.46 | $2.74 |
| Diluted shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | $120M | $102M | $78.3M | $115M | $127M | $103M | $102M | $146M | $119M | $123M |
| Capital expenditure | $49.9M | $67.5M | $110M | $37.2M | $69.8M | $125M | $105M | $121M | $77.4M | $55.0M |
| Free cash flow | $69.6M | $34.3M | β$31.4M | $78.1M | $57.3M | β$22.0M | β$3.0M | $25.6M | $42.0M | $67.5M |
| Depreciation and amortization | $52.9M | $49.8M | $46.9M | $51.4M | $54.1M | $57.7M | $56.1M | $57.0M | $67.5M | $73.6M |
| Stock-based compensation | $8.9M | $10.6M | $12.5M | $12.1M | $11.3M | $13.0M | $13.2M | $17.3M | $20.8M | $13.8M |
| Acquisitions | $0.0M | $0.0M | $264M | $0.0M | $0.0M | $0.0M | $14.7M | $0.0M | $99.3M | $20.7M |
| Share buybacks | $0.3M | $5.2M | $31.8M | $0.9M | $1.6M | $11.5M | $23.6M | $20.1M | $50.8M | $38.2M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $4.2M | $5.0M | $5.9M | $6.4M |
| Dividends and buybacks | $0.3M | $5.2M | $31.8M | $0.9M | $1.6M | $11.5M | $27.8M | $25.1M | $56.7M | $44.6M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $20.8M | $50.9M | $37.4M | $32.3M | $38.5M | $45.5M | $33.3M | $66.5M | $43.9M | $38.0M |
| Total debt | $671M | $689M | $1.0B | $912M | $784M | $789M | $825M | $849M | $940M | $928M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $438M | $507M | $540M | $520M | $565M | $628M | $637M | $699M | $681M | $669M |
| Current liabilities | $293M | $281M | $299M | $296M | $292M | $286M | $324M | $326M | $326M | $227M |
| Inventory | $229M | $237M | $285M | $289M | $296M | $314M | $356M | $396M | $405M | $411M |
| Property and equipment, net | $281M | $328M | $418M | $359M | $409M | $489M | $557M | $632M | $661M | $651M |
| Total assets | $1.1B | $1.2B | $1.5B | $1.6B | $1.6B | $1.7B | $1.7B | $1.8B | $1.9B | $1.9B |
| Total liabilities | $1.1B | $1.1B | $1.4B | $1.4B | $1.3B | $1.3B | $1.3B | $1.3B | $1.4B | $1.3B |
| Shareholders' equity | $30.4M | $99.9M | $56.2M | $147M | $342M | $407M | $399M | $499M | $489M | $574M |
| Margins | ||||||||||
| Gross margin | 20.5% | 21.8% | 19.3% | 20.2% | 21.6% | 19.9% | 17.4% | 19.7% | 20.2% | 23.8% |
| Operating margin | 6.6% | 8.4% | 5.4% | 7.6% | 9.4% | 9.3% | 7.0% | 9.1% | 7.1% | 8.9% |
| EBITDA margin | 10.3% | 11.8% | 8.4% | 10.8% | 12.6% | 12.8% | 9.8% | 11.7% | 10.3% | 12.9% |
| Net margin | 2.1% | 2.0% | 1.5% | 4.1% | 7.3% | 5.1% | 3.2% | 4.1% | 2.5% | 3.0% |
| FCF margin | 4.9% | 2.3% | β2.0% | 4.8% | 3.4% | β1.3% | β0.2% | 1.2% | 2.0% | 3.6% |
| Returns | ||||||||||
| Return on capital | 9.5% | 9.0% | 4.8% | 12.1% | 11.9% | 9.9% | 7.8% | 11.3% | 7.8% | 8.1% |
| Return on capital employed | 11.5% | 14.4% | 8.0% | 10.2% | 12.2% | 11.7% | 10.0% | 13.5% | 9.6% | 10.4% |
| Return on equity | β | 44.7% | 30.0% | 65.5% | 49.9% | 22.8% | 15.7% | 19.9% | 10.6% | 10.5% |
| Return on assets | 2.7% | 2.5% | 1.8% | 4.4% | 7.7% | 5.2% | 3.8% | 5.0% | 2.8% | 3.0% |
| Growth | ||||||||||
| Revenue growth | β13.0% | 4.2% | 5.9% | 4.8% | 2.0% | 0.6% | 18.0% | 8.8% | β2.9% | β10.2% |
| Net income growth | β | β0.7% | β19.6% | 184.6% | 83.2% | β30.2% | β25.6% | 40.7% | β41.3% | 6.9% |
| EPS growth | β | β5.0% | β16.7% | 187.3% | 80.7% | β32.1% | β23.2% | 38.9% | β40.6% | 11.4% |
| FCF growth | β20.0% | β50.7% | β191.6% | β | β26.6% | β138.4% | β | β | 64.1% | 60.7% |
| Share count change | 2.5% | 4.5% | β3.1% | β1.2% | 1.5% | 2.6% | β2.8% | 1.1% | β1.2% | β4.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | 4.4x | 3.7x | 7.4x | 5.0x | 3.5x | 3.5x | 4.1x | 3.1x | 4.2x | 3.7x |
| Debt / equity | β | 6.9x | β | 6.2x | 2.3x | 1.9x | 2.1x | 1.7x | 1.9x | 1.6x |
| Interest coverage | 1.8x | 2.9x | 1.6x | 2.0x | 3.2x | 3.9x | 3.1x | 2.8x | 1.9x | 2.5x |
| Current ratio | 1.5x | 1.8x | 1.8x | 1.8x | 1.9x | 2.2x | 2.0x | 2.1x | 2.1x | 2.9x |
| Quick ratio | 0.7x | 1.0x | 0.9x | 0.8x | 0.9x | 1.1x | 0.9x | 0.9x | 0.9x | 1.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.5% | 4.6% | 7.0% | 2.3% | 4.2% | 7.5% | 5.3% | 5.6% | 3.7% | 2.9% |
| Stock comp / revenue | 0.6% | 0.7% | 0.8% | 0.7% | 0.7% | 0.8% | 0.7% | 0.8% | 1.0% | 0.7% |
| Payouts / FCF | 0.4% | 15.2% | β | 1.2% | 2.8% | β | β | 98.1% | 135.0% | 66.1% |
| Quality scores | ||||||||||
| Piotroski F-score | 7.0 | 8.0 | 5.0 | 7.0 | 7.0 | 5.0 | 5.0 | 8.0 | 5.0 | 8.0 |
| Altman Z'' | 1.4 | 2.1 | 1.6 | 1.8 | 2.5 | 2.9 | 2.8 | 3.2 | 3.0 | 3.5 |
| Accruals ratio | β8.2% | β6.4% | β4.1% | β3.2% | β0.3% | β1.1% | β2.3% | β3.2% | β3.6% | β3.5% |
Source: SEC EDGAR XBRL filings (CIK 0001315257). Data updated October 21, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.